tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
terbinafin bluefish 250 mg
bluefish pharmaceuticals ab - terbinafinhydroklorid - tablett - 250 mg
terbinafin hexal 250 mg
hexal a/s - terbinafinhydroklorid - tablett - 250 mg
lamisil 1 % w/w
karo healthcare ab - terbinafinhydroklorid - liniment, oppløsning - 1 % w/w
onytec 80 mg/ g
polichem sa - ciklopiroks - medisinsk neglelakk - 80 mg/ g
terbinafin hexal 10 mg/ g
hexal a/s - terbinafinhydroklorid - krem - 10 mg/ g
terbinafin orifarm 250 mg
orifarm generics (3) - terbinafinhydroklorid - tablett - 250 mg
terbinafin ratiopharm 10 mg/ g
ratiopharm gmbh - terbinafinhydroklorid - krem - 10 mg/ g
advate
takeda manufacturing austria ag - octocog alfa - hemofili a - antihemoragika - behandling og profylakse av blødning hos pasienter med hemofili a (medfødt faktor viii-mangel). advate inneholder ikke von willebrand faktor i farmakologisk effektive mengder, og er derfor ikke indisert i genet for von willebrand disease.